Clinical Trial Update: Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer [Phase 2]

View source ↗

Summary

A Phase II study of Genistein (Isoflavone G-2535) in bladder cancer has completed and results were posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Bladder Carcinoma

Drugs mentioned

• Genistein (genistein)
• Isoflavone G-2535 (genistein)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Bladder Carcinoma, Stage I Bladder Cancer AJCC v6 and v7 | Phase 2 | Status: COMPLETED | Results posted: 2016-03-24